BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36197314)

  • 21. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
    Hassan HT; Zander A
    Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD34 immunohistochemistry in bone marrow biopsies for early response assessment in acute myeloid leukemia.
    Jain S; Mahapatra M; Pati HP
    Int J Lab Hematol; 2015 Dec; 37(6):746-51. PubMed ID: 26248894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
    Treaba DO; Bonal DM; Chorzalska A; Castillo-Martin M; Oakes A; Pardo M; Petersen M; Schorl C; Hopkins K; Melcher D; Zhao TC; Liang O; So EY; Reagan J; Olszewski AJ; Butera J; Anthony DC; Rintels P; Quesenberry P; Dubielecka PM
    Br J Haematol; 2023 Mar; 200(6):740-754. PubMed ID: 36354085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perturbation in the ability of bone marrow stroma from patients with acute myeloid leukemia but not chronic myeloid leukemia to support normal early hematopoietic progenitor cells.
    Sparrow RL; O'Flaherty E; Blanksby TM; Szer J; Van Der Weyden MB
    Leuk Res; 1997 Jan; 21(1):29-36. PubMed ID: 9029183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.
    Martínez A; San Miguel JF; Vidriales MB; Ciudad J; Caballero MD; López-Berges MC; Moro MJ; Calmuntia MJ; Ortega F; Orfao A
    Cytometry; 1999 Apr; 38(2):70-5. PubMed ID: 10323219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
    Feller N; Kelder A; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Cytometry B Clin Cytom; 2008 Jan; 74(1):9-16. PubMed ID: 18061946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
    Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
    Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
    Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
    Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD117/CD34 expression in leukemic blasts.
    Wells SJ; Bray RA; Stempora LL; Farhi DC
    Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
    Jamy O; Bae S; Costa LJ; Erba HP; Papadantonakis N
    Leuk Res; 2018 Nov; 74():64-67. PubMed ID: 30300822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.
    Terstappen LW; Safford M; Unterhalt M; Könemann S; Zurlutter K; Piechotka K; Drescher M; Aul C; Büchner T; Hiddemann W
    Leukemia; 1992 Oct; 6(10):993-1000. PubMed ID: 1383649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
    Jentzsch M; Bill M; Nicolet D; Leiblein S; Schubert K; Pless M; Bergmann U; Wildenberger K; Schuhmann L; Cross M; Pönisch W; Franke GN; Vucinic V; Lange T; Behre G; Mrózek K; Bloomfield CD; Niederwieser D; Schwind S
    Am J Hematol; 2017 Apr; 92(4):388-396. PubMed ID: 28133783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemic Stem Cell (CD34
    Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
    Ragusa M; Avola G; Angelica R; Barbagallo D; Guglielmino MR; Duro LR; Majorana A; Statello L; Salito L; Consoli C; Camuglia MG; Di Pietro C; Milone G; Purrello M
    BMC Cancer; 2010 Jul; 10():377. PubMed ID: 20642818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.